glp 1 approved for type 1 diabetes GLP-1-based therapies diabetes, obesity and beyond GLP-1 Receptor Agonists as Treatments

Somatostatin receptor ligands in the treatment of acromegaly

In the Phase IV study, semaglutide will be evaluated for its effects on improving depressive symptoms over 26 weeks in patients with major depressive disorder who also have overweight or obesity (Vinberg, 2026, ID NCT07136714)

The clinical trials needed to establish safety and efficacy in this population are still underway

A waist-worn accelerometer can function as an objective motor diary, deriving ON/OFF and dyskinesia biomarkers from continuous recordings [181]

It also allows taxpayers to take advantage of specialized rules, such as lower tax rates for long-term capital gains